Meeting
2024 ASCO Annual Meeting
Feasibility of tumor-informed circulating tumor DNA (ctDNA) for molecular residual disease (MRD) assessment in pediatric patients with solid tumors.
Authors
Michael Mitchell
The University of Texas Dell Medical School, Austin, TX
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 10058)
DOI
10.1200/JCO.2024.42.16_suppl.10058
Abstract #
10058
Poster Bd #
425
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
MRD assay to evaluate recurrence and response via a tumor-informed assessment: MARIA-Breast observational trial.
First Author: Edward D. Esplin
Poster
2023 ASCO Breakthrough
Personalized K-Track assay to detect actionable mutations and minimal residual disease in solid tumors.
First Author: Lan N Tu
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Tumor-informed patient-specific MRD monitoring analysis in colorectal cancer.
First Author: Gong Chen
Poster
2024 ASCO Breakthrough
Non-invasive minimal residual disease detection of liver cancer using circulating tumor DNA features and α-fetoprotein: A prospective study.
First Author: Yinyin Chang